InSphero Promotes Melanie Aregger to Chief Operating Officer

Share Article

Head of InSphero Diagnostics division and senior team member promoted to assume role as COO.

Melanie Aregger assumes COO role at InSphero AG

Her leadership...will continue to benefit our global growth initiatives in both the drug-testing and diagnostics markets.

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer.

Having joined InSphero in November 2013 as Business Development Manager, Ms. Aregger served on the management team and was promoted to Head of InSphero Diagnostics in 2014. There she has built up the InSphero Diagnostics business unit, while assisting in the securing of Series C financing for InSphero AG, a round which netted CHF 20MM in July 2015. Her efforts in these responsibilities recently earned Melanie the 2015 Women’s Business Award by “Megatrend Health.” In her new role as COO she will continue to drive the Diagnostics business as part of her business development responsibilities and also manage InSphero’s operations, purchasing and bioproduction functions.

InSphero CEO and co-founder Dr. Jan Lichtenberg states, “With her entrepreneurial business acumen and profound professional experience including business-model analysis, change and risk management, supply-chain optimization and product launches, Melanie Aregger has been a key member of the InSphero management team for the past two years. Her leadership as COO will continue to benefit our global growth initiatives in both the drug-testing and diagnostics markets.”

For more information about InSphero, visit http://www.insphero.com.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company’s patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero’s technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Randy Strube
InSphero AG
+1 800-779-7558 Ext: 102
Email >

Jens Kelm
InSphero AG
+41 44 515 0490
Email >
Visit website